Pregabalin Capsule
Product Images NDC 82804-207

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 82804-207). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

82804-207-60 (Image 01)

This text provides information about a medication called Pregabalin 75mg in capsule form. The medication is packaged by Proficient Rx LP and contains white to off-white granular powder in Size "4" hard gelatin capsules. Each capsule contains 75 mg of pregabalin. The capsules are imprinted with "PGBN" on the body and "75" on the cap. It is advised to dispense the accompanying Medication Guide to each patient. The product should be stored at 25°C (77°F) and kept out of reach of children.*

FDA Label Image

Equation (Pregabain Gault Equation)

This text provides a formula for calculating the estimated creatinine clearance (CLCr) in patients. The equation involves the patient's age, weight, and serum creatinine level. It also mentions a correction factor for female patients.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

This text shows the percentage of patients who experienced improvement in pain levels after taking different doses of Pregabalin three times a day along with a placebo. The data suggests higher improvement rates with increased Pregabalin dosage and shows a comparison of the percentage improvement in pain from baseline.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

This data provides a visual representation of the improvement in pain experienced by patients when comparing the effects of Pregabalin 100 mg taken three times a day with a placebo. The graph shows the percentage of patients who improved at different levels, ranging from 10% to 100%.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

This information shows the percentage of patients who experienced improvement in pain from baseline when taking different dosages of Pregabalin (300mg, 150mg, 75mg two times a day) and a placebo. The graph also illustrates the varying levels of improvement in pain, ranging from 0% to 100%.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

This summary presents the percentage of patients who experienced improvement in pain from baseline while taking different dosages of Pregabalin (200mg and 100mg three times a day) and a placebo. The chart shows the incremental increase in pain improvement from baseline in increments ranging from 10% to 90% and highlights the treatment efficacy.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

This text provides information on the percentage of patients improved and the corresponding percentage improvement in pain from baseline for different dosages of Pregabalin and placebo. It shows the percentage of patients improved for pregabalin doses of 100mg three times a day, 50mg three times a day, and a placebo. Additionally, it indicates the pain improvement percentages ranging from greater than 10% to greater than 90% compared to the baseline.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

This data table shows responder rates for different dosages of a drug across various studies. The responder rate is given as a percentage for each dosage regimen, with details such as BID (twice a day) and TID (three times a day) mentioned. The table also indicates statistically significant differences compared to a placebo group for some dosages.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

This is a report showing statistical data related to doses in a study. The data includes significance levels (p-values) for different dose groups. The graph displays the doses in milligrams per day and identifies the "Placebo" group for comparison. The p-values indicate the statistical significance of the differences observed between the dose groups.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

This data represents the percentage of patients who experienced improvement in pain levels after different doses of pregabalin and a placebo. The chart shows the percentage improvement in pain from the baseline for each group. The values range from 20% to 100%, with varying numbers of patients in each category. The highest percentage improvement is for the 600 mg daily dose of pregabalin.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

This appears to be a table displaying estimated percentages of subjects without LIR (Likely Inhibitory Response) for different doses of Pregabalin and a Placebo, over a period of days. The data points range from 0% to 100% and the days are labeled from 80 to 180.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

This text shows the percentage of subjects improved with Pregabalin compared to Placebo from baseline to week 12. The graph displays the percentage improved at different intervals from 0 to 100.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

This text outlines the percentage of subjects who showed improvement after taking Pregabalin compared to Placebo from baseline to week 16 using the BOCF method. The data includes different percentage ranges indicating the level of improvement in subjects. The text also provides a clear numerical breakdown for each group.*

FDA Label Image

Str (Pregabalin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.